Current developments in technology transfer to a Contract Development and Manufacturing Organization (CDMO)

Senior Manager Roberto Formisano Discusses Challenges of Technology Transfer and Predicts Future Trends in Cell and Gene Therapy Industry

Roberto Formisano, Process Transfer Senior Manager at AGC Biologics, shares his thoughts on the challenges of technology transfer. He discusses the nuances of this process, both from development to GMP manufacturing and from a customer to a contract development and manufacturing organization (CDMO). One of the key challenges he highlights is the critical timelines that are essential in technology transfer. Balancing the number of batches needed for sufficient quality data while adhering to these timelines is a significant challenge in the industry.

In addition to discussing timelines, Roberto also talks about his predictions on technology and manufacturing trends that are expected to shape the cell and gene therapy industry by 2024. His insights provide valuable perspectives on the future direction of the industry.

Roberto had an interview with EPR editor Caroline Peachey at Terrapin’s Advanced Therapies conference in London on 19 March. The interview sheds light on the complexities of technology transfer and offers valuable insights into the industry’s challenges and opportunities.

Leave a Reply

NFL owners greenlight major alterations to Hard Knocks: Up to five teams may be showcased annually Previous post Hard Knocks” Gets a Makeover: Four Teams in One Division and New Eligibility Criteria for 2024
What we know so far about the Baltimore bridge collapse: reminiscent of an action movie Next post The Daring Rescue: A Tragic Accident and Its Implications for the US Automotive Supply Chain”.